The stock of G1 Therapeutics Inc (GTHX) has seen a 23.45% increase in the past week, with a 21.77% gain in the past month, and a 1.13% flourish in the past quarter. The volatility ratio for the week is 7.54%, and the volatility levels for the past 30 days are at 10.92% for GTHX. The simple moving average for the last 20 days is 18.54% for GTHX stock, with a simple moving average of -27.93% for the last 200 days.

Is It Worth Investing in G1 Therapeutics Inc (NASDAQ: GTHX) Right Now?

Additionally, the 36-month beta value for GTHX is 1.74. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 1 rating it as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price predicted by analysts for GTHX is $8.40, which is $6.61 above the current price. The public float for GTHX is 42.97M and currently, short sellers hold a 5.67% ratio of that float. The average trading volume of GTHX on November 20, 2023 was 515.08K shares.

GTHX) stock’s latest price update

The stock price of G1 Therapeutics Inc (NASDAQ: GTHX) has surged by 14.01 when compared to previous closing price of 1.57, but the company has seen a 23.45% gain in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-01 that G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Will Roberts – Vice President-Communications Jack Bailey – Chief Executive Officer Andrew Perry – Chief Commercial Officer Raj Malik – Chief Medical Officer John Umstead – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Dane Leone – RJF Anupam Rama – JPMorgan Troy Langford – TD Cowen Operator Good day and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2023 Financial Results Call.

Analysts’ Opinion of GTHX

Many brokerage firms have already submitted their reports for GTHX stocks, with JP Morgan repeating the rating for GTHX by listing it as a “Neutral.” The predicted price for GTHX in the upcoming period, according to JP Morgan is $10 based on the research report published on January 30, 2023 of the current year 2023.

GTHX Trading at 27.50% from the 50-Day Moving Average

After a stumble in the market that brought GTHX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.69% of loss for the given period.

Volatility was left at 10.92%, however, over the last 30 days, the volatility rate increased by 7.54%, as shares surge +32.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.95% upper at present.

During the last 5 trading sessions, GTHX rose by +29.31%, which changed the moving average for the period of 200-days by -76.30% in comparison to the 20-day moving average, which settled at $1.5332. In addition, G1 Therapeutics Inc saw -67.03% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at GTHX starting from Velleca Mark A., who sale 60,000 shares at the price of $2.00 back on Aug 08. After this action, Velleca Mark A. now owns 116,000 shares of G1 Therapeutics Inc, valued at $119,974 using the latest closing price.

Bailey John E. (Jack) Jr., the President and CEO of G1 Therapeutics Inc, sale 2,719 shares at $2.45 during a trade that took place back on Jul 05, which means that Bailey John E. (Jack) Jr. is holding 433,563 shares at $6,672 based on the most recent closing price.

Stock Fundamentals for GTHX

Current profitability levels for the company are sitting at:

The net margin for G1 Therapeutics Inc stands at -287.63. The total capital return value is set at -71.84, while invested capital returns managed to touch -78.31. Equity return is now at value -158.99, with -47.21 for asset returns.

Based on G1 Therapeutics Inc (GTHX), the company’s capital structure generated 121.85 points at debt to equity in total, while total debt to capital is 54.92. Total debt to assets is 44.56, with long-term debt to equity ratio resting at 120.19. Finally, the long-term debt to capital ratio is 54.18.

When we switch over and look at the enterprise to sales, we see a ratio of 0.26, with the company’s debt to enterprise value settled at 0.48. The receivables turnover for the company is 6.11 and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.04.


In conclusion, G1 Therapeutics Inc (GTHX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.